<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777552</url>
  </required_header>
  <id_info>
    <org_study_id>2015/298</org_study_id>
    <nct_id>NCT04777552</nct_id>
  </id_info>
  <brief_title>Fixed-schedule Benzodiazepine Dosing vs Based on a CIWA-Ar Alcohol Protocol in Alcohol Detoxification.</brief_title>
  <official_title>The Use of Fixed-schedule Benzodiazepine Dosing Versus Treatment Based on a CIWA-Ar Alcohol Protocol in Alcohol Detoxification.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Does the use of a symptom-triggered therapy (with assessment making use of a CIWA-Ar scale)&#xD;
      decrease the total amount of benzodiazepines given to patients with alcohol dependence and&#xD;
      are less patients still dependent on benzodiazepines on their departure in comparison with&#xD;
      the use of a fixed-schedule dose of benzodiazepines?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology This study will be a retrospective study using administrative and clinical&#xD;
      patient data of patients presenting for alcohol detoxification at the Psychiatry department&#xD;
      of the Universitair Ziekenhuis Brussel. Two periods in the data will be compared. One period&#xD;
      will be consisting of patient data before 2013 when the hospital still used the&#xD;
      fixed-schedule dosing of benzodiazepines. The other period will be consisting of patient data&#xD;
      after 2013 when the hospital switched to the symptom-triggered prescription of&#xD;
      benzodiazepines.&#xD;
&#xD;
      Inclusion &amp; Exclusion criteria Inclusion criteria are patients with the age of 18 years or&#xD;
      older who were treated for alcohol .dependence at the UZ Brussel in one of the periods stated&#xD;
      above. The criteria for exclusion were found in the literature and include pregnancy, use of&#xD;
      central nervous system (CNS) depressant agents, history of dementia, acute psychosis, and&#xD;
      severe hepatic dysfunction (15-18). Comorbid benzodiazepine dependence. A history of severe&#xD;
      epilepsy on withdrawal,… Outcomes The main outcome measures will be the total amount of&#xD;
      benzodiazepines given during the hospital stay, whether the patient is still dependent on&#xD;
      benzodiazepines when leaving the hospital, the length of the hospital stay, and some baseline&#xD;
      patient characteristics. These patient characteristics will include age, sex, race/ethnic&#xD;
      group, primary reason for hospitalization, body mass index (BMI), blood alcohol level (BAL)&#xD;
      on admission, international normalized ratio (INR), diagnosis of co-morbid psychiatric&#xD;
      disorder, history of other substance abuse, indicators of withdrawal severity (e.g. CIWA-Ar,&#xD;
      tremor, seizures), discharge medications, benzodiazepine dose administered (15-18).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>total amount of benzodiazepines administrated</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Alcoholdependence</condition>
  <condition>CIWA-R</condition>
  <condition>Benzodiazepines</condition>
  <arm_group>
    <arm_group_label>Fixed-schedule</arm_group_label>
    <description>Untill mid 2013 patients with individually determined fixed-schedule dosage of benzodiazepines in the case of alcoholdependence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIWA-Ar</arm_group_label>
    <description>Halfway through the year 2013 the department of psychiatry changed the protocol in alcohol withdrawal treatment and changed it to a symptom-triggered therapy with the use of CIWA-Ar to assess the severity of the alcohol withdrawal syndrome.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diazepam (or equivalence if other benzodiazepine)</intervention_name>
    <arm_group_label>CIWA-Ar</arm_group_label>
    <arm_group_label>Fixed-schedule</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who were treated for alcohol dependence at the UZ Brussel in one of the periods&#xD;
        stated above.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  patients who were treated for alcohol dependence at the UZ Brussel in one of the&#xD;
             periods stated above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        pregnancy, use of central nervous system (CNS) depressant agents, history of dementia,&#xD;
        acute psychosis, and severe hepatic dysfunction. Comorbid benzodiazepine dependence. A&#xD;
        history of severe epilepsy on withdrawal,…&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Dieter Zeeuws</investigator_full_name>
    <investigator_title>MD Resident Psychiatry</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diazepam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

